Abstract
Local immunopathogenesis of COVID-19 acute respiratory distress syndrome (CARDS) and the effects of systemic dexamethasone (DXM) treatment on pulmonary immunity in COVID-19 remain insufficiently understood. To provide further insight into insight into immune regulatory mechanisms in the lungs of CARDS (with and without DXM treatment) and critically ill non-COVID-19 patients (without DXM treatment), transcriptomic RNA-seq analysis of bronchoalveolar lavage fluid (BALF) was performed in these patients. Functional analysis was performed using gene ontology and a blood transcription module, and gene expression of select pro-inflammatory cytokines, interferon-stimulated genes (ISGs) and auto-IFN antibodies were assessed. We found 550 and 2173 differentially expressed genes in patients with non-DXM-CARDS and DXM-CARDS, respectively. DXM-CARDS was characterized by upregulation of genes related to pulmonary innate and adaptive immunity, notably B-cell and complement pathway activation, antigen presentation, phagocytosis and FC-gamma receptor signalling. Pro-inflammatory genes were not differentially expressed in CARDS vs. non-COVID-19, nor did they differ according to DXM. Most ISGs were specifically upregulated in CARDS, particularly in non-DXM-CARDS. Auto-IFN autoantibodies were detectable in BALF of some CARDS patients. In conclusion, DXM treatment was not associated with regulation of pro-inflammatory pathways in CARDS but with regulation of other specific local innate and adaptive immune responses.
summary This study identifies differentially expressed genes in bronchoalveolar fluid of COVID-19 acute respiratory distress patients with a distinct RNA expression profile of those treated with dexamethasone. These results challenge the concept of a COVID-19 specific cytokine storm.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04354584
Funding Statement
The following sentence was used in the manuscript: "The study was supported by the Lundbeck Foundation (grant no. R349-2020-540 to AR, RP and RMGB), the Independent Research Fund Denmark (8020-00391B to J.B.), the Danish Cancer Society (R204-A12639 to J.B.), the Novo Nordisk Foundation (NNF19OC0054518 and NNF19OC0055462 to J.B.; NNF21OC0067157 to THM) and the European Research Council (802899 to T.K.H.S)."
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Ethics Committee of Copenhagen (H-20023159/H-22011021/H-22009131) and the Knowledge Center for Data Review of Copenhagen (P-2020-399) and registered at ClinicalTrials.gov (NCT04354584).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest disclosure statement: UF, AR, RMGB, SEJ, THM, APU, TKHS, JB and RRP have no disclosures to declare.
Funding: The study was supported by the Lundbeck Foundation (grant no. R349-2020-540 to AR, RP and RMGB), the Independent Research Fund Denmark (8020-00391B to J.B.), the Danish Cancer Society (R204-A12639 to J.B.), the Novo Nordisk Foundation (NNF19OC0054518 and NNF19OC0055462 to J.B.; NNF21OC0067157 to THM) and the European Research Council (802899 to T.K.H.S).
Contact/alternate contact: Andreas Ronit, MD, PhD, Department of Infectious Diseases 144, Copenhagen University Hospital – Amager and Hvidovre, Kettegårds Allé 40; DK-2650 Hvidovre, Denmark, Tel: +45 2239 5363; E-mail: andreas.ronit.01{at}regionh.dk, Ulrik Fahnøe, MSc, PhD, Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, DK-2200 Copenhagen N, Denmark, Tel: +45 2449 4237; E-mail: ulrik{at}sund.ku.dk
All data produced in the present study are available upon reasonable request to the authors
Data Availability
The following sentence was used in the manuscript: "All data produced in the present study are available upon reasonable request to the authors"
Abbreviations
- (CARDS)
- COVID-19 acute respiratory distress syndrome
- (BALF)
- bronchoalveolar lavage fluid
- (DXM)
- dexamethasone
- (COVID-19)
- coronavirus disease 2019
- (SARS-CoV-2)
- severe acute respiratory syndrome coronavirus 2
- (ARDS)
- acute respiratory distress syndrome
- (IFN)
- interferon
- (ISGs)
- interferon stimulated genes
- (ICU)
- intensive care unit
- (GO)
- gene ontology
- (DE)
- differentially expressed
- (BTMs)
- blood transcriptome modules
- (TNF)
- tumour necrosis factor
- (GM-CF/CSF2)
- granulocyte-macrophage colony-stimulating factor
- (MCP-1/CCL2)
- monocyte chemoattractant protein-1
- (IP-10/CXCL10)
- interferon gamma-induced protein
- (MIP-1-α/CCL3)
- macrophage inflammatory protein-1
- (ELISA)
- enzyme-linked immunosorbent assay
- (IRF)
- interferon regulatory factor
- (IL)
- interleukin
